Mostrar el registro sencillo del ítem
Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
dc.contributor.author | Alvarez, X Anton | |
dc.contributor.author | Alvarez, Irene | |
dc.contributor.author | Martinez Alvarez, Antia | |
dc.contributor.author | Romero, Iria | |
dc.contributor.author | Benito, Concha | |
dc.contributor.author | Suarez, Irene | |
dc.contributor.author | Mourente, Silvia | |
dc.contributor.author | Fantini, Manuel | |
dc.contributor.author | Figueroa Rodríguez, Jesús | |
dc.contributor.author | Aleixandre, Manuel | |
dc.contributor.author | Linares, Carlos | |
dc.contributor.author | Muresanu, Dafin | |
dc.contributor.author | Winter, Stefan | |
dc.contributor.author | Moessler, Herbert | |
dc.date.accessioned | 2022-03-23T08:55:46Z | |
dc.date.available | 2022-03-23T08:55:46Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1461-1457 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32640027 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16380 | |
dc.description.abstract | Serum vascular endothelial growth factor (VEGF) increases with Alzheimer's disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial. Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels. Our results indicate that the combined therapy reversed the increase of serum VEGF in advanced AD, which was associated with cognitive and functional responses, particularly in patients with high baseline VEGF. | en |
dc.rights | Atribución-NoComercial 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject.mesh | Nootropic Agents | * |
dc.subject.mesh | Alzheimer Disease | * |
dc.subject.mesh | Vascular Endothelial Growth Factor A | * |
dc.subject.mesh | Drug Therapy | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Amino Acids | * |
dc.subject.mesh | Aged | * |
dc.title | Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease. | en |
dc.type | Journal Article | es |
dc.authorsophos | Alvarez, X Anton;Alvarez, Irene;Martinez, Antia;Romero, Iria;Benito, Concha;Suarez, Irene;Mourente, Silvia;Fantini, Manuel;Figueroa, Jesús;Aleixandre, Manuel;Linares, Carlos;Muresanu, Dafin;Winter, Stefan;Moessler, Herbert | |
dc.identifier.doi | 10.1093/ijnp/pyaa046 | |
dc.identifier.pmid | 32640027 | |
dc.identifier.sophos | 36840 | |
dc.issue.number | 9 | es |
dc.journal.title | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Atención Primaria::CENTRO SAUDE VALLE INCLAN (OURENSE) | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Rehabilitación | es |
dc.rights.accessRights | openAccess | |
dc.subject.decs | aminoácidos | * |
dc.subject.decs | anciano | * |
dc.subject.decs | enfermedad de Alzheimer | * |
dc.subject.decs | farmacoterapia | * |
dc.subject.decs | humanos | * |
dc.subject.decs | factor A de crecimiento endotelial vascular | * |
dc.subject.decs | nootrópicos | * |
dc.subject.keyword | AS Ourense AP | es |
dc.subject.keyword | CHUS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 23 | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 4.0 Internacional
![](/xmlui/themes/Mirage2//images/final_lines.png)